These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Triple therapy with salmeterol/fluticasone propionate 50/250 plus tiotropium bromide improve lung function versus individual treatments in moderate-to-severe Japanese COPD patients: a randomized controlled trial - Evaluation of Airway sGaw after treatment with tripLE. Saito T, Takeda A, Hashimoto K, Kobayashi A, Hayamizu T, Hagan GW. Int J Chron Obstruct Pulmon Dis; 2015; 10():2393-404. PubMed ID: 26604737 [Abstract] [Full Text] [Related]
5. The efficacy and safety of combined tiotropium and olodaterol via the Respimat(®) inhaler in patients with COPD: results from the Japanese sub-population of the Tonado(®) studies. Ichinose M, Taniguchi H, Takizawa A, Grönke L, Loaiza L, Voß F, Zhao Y, Fukuchi Y. Int J Chron Obstruct Pulmon Dis; 2016; 11():2017-27. PubMed ID: 27621608 [Abstract] [Full Text] [Related]
11. Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study. Sauer R, Hänsel M, Buhl R, Rubin RA, Frey M, Glaab T. Int J Chron Obstruct Pulmon Dis; 2016; 11():891-8. PubMed ID: 27217742 [Abstract] [Full Text] [Related]
13. Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide. Singh D, Corradi M, Spinola M, Papi A, Usmani OS, Scuri M, Petruzzelli S, Vestbo J. Int J Chron Obstruct Pulmon Dis; 2017; 12():2917-2928. PubMed ID: 29062229 [Abstract] [Full Text] [Related]
14. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design. Rennard SI, Martinez FJ, Rabe KF, Sethi S, Pizzichini E, McIvor A, Siddiqui S, Anzueto A, Zhu H. Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416 [Abstract] [Full Text] [Related]
15. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy. Mapel D, Laliberté F, Roberts MH, Sama SR, Sundaresan D, Pilon D, Lefebvre P, Duh MS, Patel J. Int J Chron Obstruct Pulmon Dis; 2017; 12():1825-1836. PubMed ID: 28684905 [Abstract] [Full Text] [Related]
16. Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study. Kerwin EM, Kalberg CJ, Galkin DV, Zhu CQ, Church A, Riley JH, Fahy WA. Int J Chron Obstruct Pulmon Dis; 2017; 12():745-755. PubMed ID: 28280319 [Abstract] [Full Text] [Related]
17. Combination therapy of inhaled steroids and long-acting beta2-agonists in asthma-COPD overlap syndrome. Lee SY, Park HY, Kim EK, Lim SY, Rhee CK, Hwang YI, Oh YM, Lee SD, Park YB. Int J Chron Obstruct Pulmon Dis; 2016; 11():2797-2803. PubMed ID: 27877033 [Abstract] [Full Text] [Related]